The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
single lesion and longest tumor diameter were 5-10cm;
CP-A or B classification;
Eastern Cooperative Oncology Group (ECOG) score 0-1;
tumor thrombus;
lymph node involvement;
extrahepatic metastasis.